Search
Diflunisal
go.drugbank.com/drugs/DB00861ApprovedDiflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though it...
Protein S human
go.drugbank.com/drugs/DB13149ApprovedInvestigationalProtein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade.
Cefmenoxime
go.drugbank.com/drugs/DB00267ApprovedCefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of...
Fenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnIt is listed as an illicit substance in many countries due to addiction issues and listed as a prohibited substance by the World Anti-Doping Agency. … clinical practice, central nervous system stimulative effects are less notorious than with some other agents such as diethylpropion and mazindol. [7] In the United States fenproporex was never approved by
Dimenhydrinate
go.drugbank.com/drugs/DB00985ApprovedInvestigationaleffects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade. … [A33889] When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation.
Coenzyme M
go.drugbank.com/drugs/DB09110ApprovedInvestigationalCoenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]
Troglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnIt was superseded by [pioglitazone] and [rosiglitazone].
Dextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]
Valaciclovir
go.drugbank.com/drugs/DB00577ApprovedInvestigationalIt was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline [L5671]. Valacyclovir is the L-valine ester of aciclovir. … It is caused by infection with the herpes simplex virus (HSV). Infection with this virus is lifelong with periodic episodes of reactivation [A175903].